수막염 진단 검사 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the meningitis diagnostic testing market size was valued at USD 123.86 million in 2025 and estimated to grow from USD 128.1 million in 2026 to reach USD 151.53 million by 2031, at a CAGR of 3.42% during the forecast period (2026-2031).

This report is Segmented by Test Type (Latex Agglutination Test, Lateral Flow Assay, and More), Technology (Molecular Diagnostics, Immunoassays and More), Sample Type (Cerebrospinal Fluid, Blood/Serum and More), Pathogen (Bacterial, Viral and More) End-User (Hospital, Diagnostics Centers, and More), and Geography (North America and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Meningitis Diagnostic Testing Market Trends and Insights

Rise In Global Meningitis Incidence

Surveillance confirms that bacterial meningitis still claims 10-15% case-fatality despite vaccine progress.Sub-Saharan Africa reported 2,370 suspected cases and 178 deaths in the 2023-2024 season, underscoring the persisting diagnostic need. Antimicrobial resistance in Streptococcus pneumoniae and Neisseria meningitidis increases urgency for rapid pathogen identification. Asia-Pacific remains under-diagnosed owing to weak surveillance, hinting at latent volume once labs scale up. Urbanization and climate shifts may alter transmission patterns, making early detection integral to outbreak control. Together, these forces keep the meningitis diagnostic testing market on a steady growth track.

Growing Adoption Of Syndromic Multiplex PCR Panels

Hospital systems now favor panels that detect up to 14 meningitis pathogens from one CSF specimen in under an hour. Academic centers adopting the BioFire FilmArray panel trimmed median antibiotic courses from 3 days to 2 days while boosting de-escalation rates by 46%. Faster rule-out improves bed turnover and supports value-based care. Pediatric wards gain assurance, as sensitivity for Group B Streptococcus tops 100% in culture-negative cases. Cost-offset studies find savings through shorter stays that outweigh kit expense. These operational wins move multiplex PCR into routine practice, lifting the meningitis diagnostic testing market.

High CAPEX/OPEX Of Multiplex Molecular Instruments

PCR systems range from USD 100,000 to 300,000 and charge USD 50-150 per cartridge, locking out small laboratories. Ethiopian hospitals report FilmArray reagent costs exceeding annual budgets even when clinical benefits are clear. Leasing schemes exist, but few institutions possess financing capacity. Low-volume sites cannot amortize fixed costs, making price a brake on the meningitis diagnostic testing market.

Other drivers and restraints analyzed in the detailed report include:

1. Hospital Stewardship Programs Targeting Rapid Rule-Out
2. Decentralization Toward Point-Of-Care Testing In Low-Resource Settings
3. Limited CSF Sample Availability In Pediatric Settings

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

CRISPR assays log the fastest 6.49% CAGR yet PCR retains 42.87% of 2025 revenue. The meningitis diagnostic testing market continues to lean on PCR because clinicians trust its sensitivity, and hospital labs already own compatible cyclers. However, CRISPR-Cas split-luciferase methods now detect attomolar nucleic acid directly from CSF in 20 minutes, matching syndromic panel breadth. Lateral-flow strips stay relevant in outreach campaigns where no electricity is guaranteed. ELISA gradually declines as molecular specificity rises. Culture's share erodes further when patients arrive pre-treated with antibiotics that inhibit growth.

Demand shifts toward rapid rule-out: multiplexed isothermal assays reach 10 fg detection of Neisseria meningitidis, aiding outbreak triage in the African belt. Latex agglutination still gives value in field tents because it stores ambient, though sensitivity limits remain. Artificial-intelligence imaging that reads culture plates promises to salvage legacy workflows by automating detection, so legacy and novel technologies coexist, creating layered opportunities within the meningitis diagnostic testing market.

By 2031, CRISPR penetration in mid-income hospitals will challenge PCR's leadership, yet the coexistence of low-tech and high-tech solutions reflects buyer heterogeneity. Vendors therefore maintain mixed portfolios, balancing high-complexity panels for tertiary centers with robust lateral-flow kits for outreach. This dual strategy enlarges addressable volumes and mitigates single-technology risk.

Molecular diagnostics represented 49.12% share in 2025, but NGS's 6.88% CAGR positions it as a prime disruptor. Metagenomic sequencing achieved 60.6% positivity versus 20.2% for conventional CSF methods in one hospital cohort. Its aptitude for unknown or mixed infections drives adoption in neurologic ICUs where unexplained encephalitis persists. Immunoassays defend niche point-of-care roles thanks to minimal training needs, while classic culture remains essential for susceptibility profiling even as throughput declines.

NGS now returns actionable reads in <6 hours on low-capacity benchtop sequencers, letting clinicians target therapy within the admission window. Cloud bioinformatics portals handle analytics, reducing local staffing dependencies. However, costs per sample still average USD 175, limiting routine use outside research centers. Over the forecast, reagent price drops and pay-per-sample business models are likely to send NGS deeper into routine microbiology, lifting the meningitis diagnostic testing market size devoted to sequencing applications.

Complete Report Scope:

• By Test Type
  • Latex Agglutination Tests
  • Lateral-Flow Assay
  • PCR Assay
  • ELISA Tests
  • Culture Test
  • CRISPR-based Assay
• By Technology
  • Molecular Diagnostics
  • Immunoassays
  • Microbiology / Culture
  • Next-Generation Sequencing
• By Sample Type
  • Cerebrospinal Fluid (CSF)
  • Blood / Serum
  • Nasopharyngeal Swab
  • Others (Urine, Saliva)
• By Pathogen
  • Bacterial
  • Viral
  • Fungal
  • Parasitic
• By End User
  • Hospitals
  • Diagnostic Centers
  • Academic & Research Labs
  • Others (POC Clinics, Military, NGOs)
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America commanded 37.65% revenue in 2025, enabled by payer coverage and FDA pathways that fast-track infectious disease assays. Hospitals integrate rapid panels into stewardship dashboards, trimming average length of stay and unlocking bed capacity. Canada expands coverage through provincial lab modernization grants, while Mexico's Seguro Popular reforms channel funds to regional diagnostic hubs. Despite leadership, budget scrutiny prompts negotiations on reagent pricing to maintain sustainable volumes in mature markets.

Asia-Pacific is the top growth engine at 5.95% CAGR through 2031. China funds hospital laboratory automation in its Healthy China 2030 plan, boosting uptake of NGS and multiplex PCR. India scales newborn screening under Ayushman Bharat, increasing routine bacterial panels. Japan emphasizes rapid viral differentiation in pediatric wards to cut antibiotic misuse. Southeast Asian nations upgrade meningitis surveillance post-COVID-19, aligning vaccine programs with better diagnostic confirmation. These initiatives collectively swell the meningitis diagnostic testing market in the region.

Europe posts steady gains as antimicrobial resistance watchlists drive molecular demand. Germany and France pilot metagenomic sequencing reimbursement, and the United Kingdom applies value-based procurement for point-of-care kits across the National Health Service. Eastern European modernization grants fund cold-chain upgrades that support reagent stability. Cross-border data sharing through the European Centre for Disease Prevention and Control harmonizes testing protocols, providing scale benefits to suppliers. Market uptake thus remains consistent, though pricing pressures persist under single-payer systems.

1. Abbott Laboratories
2. Beckton Dickinson
3. bioMerieux
4. Bio-Rad Laboratories
5. Danaher
6. Elitech Group
7. Roche
8. GenMark Diagnostics
9. Hologic
10. IMMY
11. DiaSorin
12. Oxford Nanopore Technologies
13. QIAGEN
14. Seegene
15. Siemens Healthineers
16. Thermo Fisher Scientific
17. Trinity Biotech
18. Tosoh
19. Meridian Bioscience
20. Quanterix Corporation

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rise In Global Meningitis Incidence
  • 4.2.2 Growing Adoption Of Syndromic Multiplex PCR Panels
  • 4.2.3 Hospital Stewardship Programs Targeting Rapid Rule-Out
  • 4.2.4 Decentralization Toward Point-Of-Care (POC) Testing In Low-Resource Settings
  • 4.2.5 National Newborn Screening Mandates For Bacterial Meningitis
  • 4.2.6 Pandemic-Driven Investment In Molecular Infrastructure
• 4.3 Market Restraints
  • 4.3.1 High CAPEX/OPEX Of Multiplex Molecular Instruments
  • 4.3.2 Limited CSF Sample Availability In Paediatric Settings
  • 4.3.3 Persisting Reimbursement Gaps For Rapid POC Tests
  • 4.3.4 Cold-Chain Logistics Constraints In LMICs
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technology Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size and Growth Forecasts (Value-USD)

• 5.1 By Test Type
  • 5.1.1 Latex Agglutination Tests
  • 5.1.2 Lateral-Flow Assay
  • 5.1.3 PCR Assay
  • 5.1.4 ELISA Tests
  • 5.1.5 Culture Test
  • 5.1.6 CRISPR-based Assay
• 5.2 By Technology
  • 5.2.1 Molecular Diagnostics
  • 5.2.2 Immunoassays
  • 5.2.3 Microbiology / Culture
  • 5.2.4 Next-Generation Sequencing
• 5.3 By Sample Type
  • 5.3.1 Cerebrospinal Fluid (CSF)
  • 5.3.2 Blood / Serum
  • 5.3.3 Nasopharyngeal Swab
  • 5.3.4 Others (Urine, Saliva)
• 5.4 By Pathogen
  • 5.4.1 Bacterial
  • 5.4.2 Viral
  • 5.4.3 Fungal
  • 5.4.4 Parasitic
• 5.5 By End User
  • 5.5.1 Hospitals
  • 5.5.2 Diagnostic Centers
  • 5.5.3 Academic & Research Labs
  • 5.5.4 Others (POC Clinics, Military, NGOs)
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
  • 6.3.1 Abbott
  • 6.3.2 Becton, Dickinson and Company
  • 6.3.3 bioMerieux
  • 6.3.4 Bio-Rad Laboratories
  • 6.3.5 Danaher
  • 6.3.6 ELITechGroup
  • 6.3.7 F. Hoffmann-La Roche Ltd.
  • 6.3.8 GenMark Diagnostics
  • 6.3.9 Hologic Inc.
  • 6.3.10 IMMY
  • 6.3.11 DiaSorin S.p.A.
  • 6.3.12 Oxford Nanopore Technologies
  • 6.3.13 QIAGEN N.V.
  • 6.3.14 Seegene Inc.
  • 6.3.15 Siemens Healthineers
  • 6.3.16 Thermo Fisher Scientific
  • 6.3.17 Trinity Biotech
  • 6.3.18 Tosoh Corporation
  • 6.3.19 Meridian Bioscience
  • 6.3.20 Quanterix Corporation

7 Market Opportunities and Future Outlook

• 7.1 White-Space and Unmet-Need Assessment